Vanguard Capital Management
ACRS icon

Vanguard Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Vanguard Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.8M Buy
5,817,866
+650,397
+13% +$2.9M ﹤0.01% 2202
2026
Q1 		$19.4M Buy
+5,167,469
New +$17.4M ﹤0.01% 2358

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management's ACRS Position: Q2 2026 in Review

Vanguard Capital Management increased its Aclaris Therapeutics (ACRS) stake by 13% in Q2 2026, buying an estimated $2.9M and bringing the position to 5,817,866 shares worth $30.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2202.

Vanguard Capital Management first reported a position in ACRS in Q1 2026 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Vanguard Capital Management held 5,817,866 shares of Aclaris Therapeutics worth $30.8M as of Q2 2026.
  • Vanguard Capital Management bought 650,397 Aclaris Therapeutics shares in Q2 2026, an estimated $2.9M.
  • Aclaris Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2202 holding.
  • Vanguard Capital Management first reported a position in Aclaris Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.